Carotenoid intakes and risk of breast cancer defined by estrogen receptor and progesterone receptor status: a pooled analysis of 18 prospective cohort studies
View/ Open
7149 ajcn9530713.pdf (133.3Kb)
Access Status
Full text of the requested work is not available in DASH at this time ("restricted access"). For more information on restricted deposits, see our FAQ.Author
Zhang, Xuehong
Spiegelman, Donna
Baglietto, Laura
Bernstein, Leslie
Boggs, Deborah
van den Brandt, Piet A.
Buring, Julie
Gapstur, Susan
Giles, Graham
Giovannucci, Edward
Goodman, Gary
Hankinson, Susan
Helzlsouer, Kathy
Horn-Ross, Pamela
Inoue, Manami
Jung, Seungyoun
Khudyakov, Polyna
Larsson, Susanna
Lof, Marie
McCullough, Marjorie
Miller, Anthony
Neuhouser, Marian
Palmer, Julie
Park, Yikyung
Robien, Kim
Rohan, Thomas
Ross, Julie
Schouten, Leo
Shikany, James
Tsugane, Shoichiro
Visvanathan, Kala
Weiderpass, Elisabete
Wolk, Alicja
Willett, Walter C.::94559ea206eef8a8844fc5b80654fa5b::600
Zhang, Shumin
Ziegler, Regina
Smith-Warner, Stephanie
Published Version
https://doi.org/10.3945/ajcn.111.014415Metadata
Show full item recordCitation
Zhang, Xuehong, Donna Spiegelman, Laura Baglietto, Leslie Bernstein, Deborah A Boggs, Piet A van den Brandt, Julie E Buring, et al. 2012. “Carotenoid Intakes and Risk of Breast Cancer Defined by Estrogen Receptor and Progesterone Receptor Status: A Pooled Analysis of 18 Prospective Cohort Studies.” The American Journal of Clinical Nutrition 95 (3): 713–25. https://doi.org/10.3945/ajcn.111.014415.Abstract
Background: Epidemiologic studies examining associations between carotenoid intakes and risk of breast cancer by estrogen receptor (ER) and progesterone receptor (PR) status are limited. Objective: We investigated these associations in a pooled analysis of 18 cohort studies. Design: Of 1,028,438 participants followed for a maximum follow-up of 26 y across studies, 33,380 incident invasive breast cancers were identified. Study-specific RRs and 95% CIs were estimated by using Cox proportional hazards regression and then pooled by using a random-effects model. Results: alpha-Carotene, beta-carotene, and lutein/zeaxanthin intakes were inversely associated with the risk of ER-negative (ER-) breast cancer (pooled multivariable RRs of the comparison between the highest and lowest quintiles): alpha-carotene (0.87; 95% CI: 0.78, 0.97), beta-carotene (0.84; 95% CI: 0.77, 0.93), and lutein/zeaxanthin (0.87; 95% CI: 0.79, 0.95). These variables were not inversely associated with the risk of ER-positive (ER+) breast cancer (pooled multivariable RRs for the same comparison): a-carotene (1.04; 95% CI: 0.99, 1.09), beta-carotene (1.04; 95% CI: 0.98, 1.10), and lutein/zeaxanthin (1.00; 95% CI: 0.93, 1.07). Although the pooled RRs for quintile 5 for beta-cryptoxanthin were not significant, inverse trends were observed for ER- and ER+ breast cancer (P-trend <= 0.05). Nonsignificant associations were observed for lycopene intake. The associations were largely not appreciably modified by several breast cancer risk factors. Nonsignificant associations were observed for PR-positive and PR-negative breast cancer. Conclusions: Intakes of alpha-carotene, beta-carotene, and lutein/zeaxanthin were inversely associated with risk of ER-, but not ER+, breast cancer. However, the results need to be interpreted with caution because it is unclear whether the observed association is real or due to other constituents in the same food sources. Am J Clin Nutr 2012;95:713-25.Citable link to this page
http://nrs.harvard.edu/urn-3:HUL.InstRepos:41384703
Collections
- SPH Scholarly Articles [6354]
Contact administrator regarding this item (to report mistakes or request changes)